Search Results

You are looking at 1 - 4 of 4 items for :

  • physical tests x
  • Pediatrics and Juvenile Medicine x
Clear All
Open access

Ersin Kasim Ulusoy

Introduction Since ancient times, one of the most common physical complaints of mankind is headaches [ 1 ]. Having various forms, headaches affect a large part of the population and lower the quality of life by causing discomfort, limits in professional life, and problems in daily relations [ 2 , 3 ]. The International Headache Society (IHS) determined the diagnosis criteria by splitting headaches into two groups, namely, primary and secondary headaches. More than 90% of headaches are primary, and most of those consist of migraines and tension

Open access

Yelda Dere, Volkan Karakuş, Özcan Dere and Nazan Özsan

, and less commonly as extranodal disease. Herein, we report a case of synchronous MALToma and FL in a patient’s two different extranodal tissues. Clinical history A 78-year-old male patient applied to our hospital with dyspeptic symptoms. All the laboratory tests were in normal ranges, no palpable lymph node was found on physical examination, and a gastroduodenoscopy was performed. The laboratory results were normal, in addition to the lactate dehydrogenase (LDH) level of 206 U/L and b2-microglobulin level of 2.3 mg/L. The endoscopic biopsy revealed a

Open access

Jiayu Huang, Yun Lian and Sixuan Qian

. Midostaurin (MS), an oral inhibitor, had shown a therapeutic effect for wild-type and mutated FLT3 AML [ 45 ]. Superior anti-AML activity was displayed in cultured and primary FLT3-ITD–expressing AML cells administered with sequential treatment with DAC and MS [ 46 ]. A phase I study testing the efficacy and safety of AZA plus MS verified modest clinical activity [ 47 ]. Of 14 available patients, three patients achieved CR and two patients achieved hematology improvement. The median OS was 6 months. Sorafenib, another FLT3 inhibitor, was applied to FLT-3-mutant AML cells

Open access

Henu Kumar Verma, Saikrishna Lakkakula and Bhaskar V.K.S. Lakkakula

synthesized in 1869, trials for testing the safety of this drug in humans started only after a century [ 18 ]. The United States Food and Drug Administration (FDA) in 1967 approved HU for the treatment of certain solid, myeloid tumors. Further, both the US FDA and, in the European Union, the European Medicines Agency (EMA) have approved HU for the treatment of SCD in 1998 and 2007, respectively. The present review focuses on the clinical benefits of HU in SCD and enhances the current understanding of the possible mechanisms of benefit for these hemoglobinopathies. HbF